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Background: Deep brain stimulation of the subthalamic nucleus (STN DBS) reduces Parkinson 
disease (PD) motor symptoms but has unexplained, variable effects on mood.  
Objective: The study tested the hypothesis that pre-existing mood and/or anxiety disorders or 
increased symptom severity negatively affects mood response to STN DBS.    
Methods: Thirty-eight PD participants with bilateral STN DBS and on PD medications were 
interviewed with Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID) and 
completed Beck Depression Inventory (BDI) and Spielberger State Anxiety Inventory (SSAI) 
self-reports.  Subsequently, during OFF and optimal ON (clinical settings) STN DBS conditions 
and while off PD medications, motor function was assessed with the United Parkinson Disease 
Rating Scale (UPDRS, part III), and participants rated their mood with Visual Analogue Scales 
(VAS), and again completed SSAI.  VAS mood variables included anxiety, apathy, valence and 
emotional arousal.   
Results: STN DBS improved UPDRS scores and mood.  Unexpectedly, PD participants 
diagnosed with current anxiety or mood disorders experienced greater STN DBS-induced 
improvement in mood than those diagnosed with remitted disorders or who were deemed as 
having never met threshold criteria for diagnosis. BDI and SSAI scores did not modulate mood 
response to STN DBS, indicating that clinical categorical diagnosis better differentiates mood 
response to STN DBS than self-rated symptom severity.  SCID diagnosis, BDI and SSAI scores 
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Conclusions: PD participants diagnosed with current mood or anxiety disorders are more 
sensitive to STN DBS-induced effects on mood, possibly indicating altered basal ganglia 
circuitry in this group.   
Keywords: Parkison disease; subthalamic nucleus; deep brain stimulation; mood; mood 

















 Twenty-five to 40% of individuals with Parkinson disease (PD) suffer from mood and 
anxiety disorders that substantially impair quality of life [1-2]. While impairments in motor 
behavior in PD arise primarily from basal ganglia dysfunction [3], the neurobiological 
underpinnings of comorbid psychiatric disorders in PD remain less clear.  PD patients in the 
advanced stages of the disease are particularly susceptible to psychiatric symptoms [1].  Since 
patients treated with subthalamic nucleus deep brain stimulation (STN DBS) typically have 
advanced motor symptoms, they may fall within this vulnerable population.   Although PD 
patients are frequently screened for current psychiatric disorders prior to STN DBS surgery [4], 
they may have recovered at the time of screening from past illness, or may develop new 
psychiatric symptoms after surgery as the disease progresses and treatment changes. 
 PD patients with STN DBS provide a unique opportunity to investigate the neural 
underpinnings of mood and anxiety disorders in PD.  The STN may have substantial functional 
heterogeneity, given its convergent inputs from and projections to motor, limbic and associative 
cortical regions [5-8].  Growing evidence demonstrates that STN DBS, a therapy aimed at 
decreasing motor impairment and dopaminergic medication use in PD, also can alter mood [9-
10].  Some studies have found reduced depression, apathy and psychiatric symptoms with 
stimulators turned ON relative to OFF [11-13].  By contrast, case studies demonstrate that some 
patients experience adverse changes in mood-related behavior with STN DBS, including fits of 
laughter [14], hypomania [15], and severe transient depression [16-17]. Case reports [17] and 
other studies [18-19], although not designed to experimentally test whether past psychiatric 
disorders affect acute alterations in mood induced by STN DBS, highlight the importance of 
considering the effects of past and current psychiatric disorders on the mood response to STN 
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 Here, we test whether past and present psychiatric history modulate the acute effects of 
STN DBS on mood using a double-blind OFF/clinically optimal ON STN DBS experimental 
design and well-validated measures of acute mood and behavioral change.  In addition, PD 
participants refrained from dopaminergic medication overnight to reduce confounding the effects 
of STN DBS on mood [12-14].  Based on past findings from our laboratory [11], we predicted 
that STN DBS would induce beneficial acute effects on mood in PD participants without past or 
current mood or anxiety symptomatology.  By contrast, we hypothesized that STN DBS would 
acutely cause adverse alterations in mood in participants with remitted or current mood and 
anxiety symptoms based on evidence that preexisting psychiatric conditions may render PD 
patients more susceptible to adverse mood alterations induced by STN DBS [17-19]. 
Materials and methods 
Participants 
Thirty-eight participants with PD and bilateral STN-DBS were recruited from the 
Washington University in St. Louis Movement Disorders Center. Six of these participants 
previously participated in a different study that measured mood response to STN DBS [11].  
Participants were informed of all relevant risks and provided signed consent forms in accordance 
with the Declaration of Helsinki; the study was approved by the Washington University in St. 
Louis Human Research Protection Office. Subjects were included based on clinically definite 
diagnosis of PD [20-22], previously implanted bilateral STN-DBS electrodes and an absence of 
neurological deficits including dementia, head injury or stroke. Details regarding the specific 
surgical technique used to implant DBS electrodes and the programming paradigm can be found 
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DBS implants were previously optimized for motor benefit using monopolar stimulation prior to 
recruitment into the study.  
Localization of STN DBS electrode contacts 
Pre-operative clinical MRIs were obtained with a Siemens Vision 1.5T scanner.  MRIs 
were aligned to post-operative computed tomography (CT) images and atlas registration was 
performed using a validated method [24].  The atlas location of each electrode contact was 
visualized by overlaying the fused MRI-CT image (resliced to match the Mai atlas [25]) on Mai 
atlas slices where contact coordinates were plotted [24]. 
Behavioral protocol 
The experimental procedure is diagrammed in Figure 1 and described below. 
Initial Interview 
  Prior to contact manipulation days, subjects were evaluated with their clinically-
determined optimal STN DBS stimulation settings while on anti-parkinsonian medications 
(optimal ON DBS, on medications) (see Figure 1). Presence of current or remitted mood or 
anxiety disorders was determined by administration of the Structural Clinical Interview for 
DSM-IV-TR Axis I Disorders (SCID-I/NP [26]) by a movement disorders-trained 
neuropsychiatrist (KJB), except that the DSM-IV-TR causation criteria were ignored as 
suggested by a consensus panel [27], e.g. Major Depressive Disorder was diagnosed rather than 
Mood Disorder Due to Parkinson Disease. Current depressive and anxiety symptoms were 
further assessed by 2 self-report questionnaires: the Beck Depression Inventory-II (BDI-II [28]) 
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For some analyses (described below), the SCID was used to separate groups of 
participants based on the presence of a threshold-level (as defined by the SCID and as 
determined by the interviewing psychiatrist) current (threshold criteria met during the last 
month) or remitted mood or anxiety disorder.  The union of these two groups includes all 
subjects who were diagnosed with past and/or current mood and/or anxiety disorders during the 
Initial Interview.  Due to low numbers of participants who were diagnosed with current mood 
disorders, we did not analyze these disorders separately.  Diagnoses of participants with other 
Axis I disorders (psychosis, substance abuse or dependence, somatoform or eating disorders) did 
not occur frequently enough in this sample for reliable data analysis.   
 Contact Manipulation Days 
One to 7 days after the Initial Interview, participants underwent electrode contact 
manipulation days, during which they underwent a series of stimulation conditions including 
OFF DBS and off PD medications, and clinically optimal settings ON DBS and off PD 
medications.  Participants abstained from PD medications overnight prior to contact 
manipulation days and were in the ‘practical defined off state’ [30].  Participants continued to 
take other medications, including psychiatric medications, and received optimal ON DBS until 
the first contact manipulation of the dayOptimal ON DBS, off PD medications was always the 
last stimulation condition of the day.  The order of other stimulation conditions was randomized 
over 1-2 days (see Figure 1).  In studies lasting 2 days, an OFF condition occurred on each day 
and data collected from these conditions were averaged to obtain average OFF scores.   Motor 
and mood outcomes were obtained 30-60 min following each contact manipulation (STN DBS 
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During each stimulation condition, motor signs were evaluated by a trained clinician 
blind to stimulation condition using the motor subscale (part III) of the Unified Parkinson’s 
Disease Rating Scale (UPDRS [31]).  Self-rated mood was measured by visual analogue scales 
(VAS [32]) and the SSAI (“state” only).  VAS ratings were linked to the Circumplex Model of 
emotion [33].  The following summary measures were used as dependent variables: valence and 
emotional arousal (calculated as described in [34]), anxiety (average of responses to VAS items 
with anchors calm/nervous, relaxed/distressed, and calm/tense), and apathy (response to a VAS 
with anchors motivated/apathetic).  For clarity in graphic representation, anxiety and apathy 
scores were reversed by subtracting the raw score from 50 so that scores are centered at zero and 
lower scores indicate lower anxiety or apathy.  
Data analyses 
For analyses described below, dependent variables included UPDRS scores, VAS 
anxiety, apathy, valence and emotional arousal scores, and SSAI anxiety scores, all obtained on 
contact manipulation days, which included OFF DBS, off PD medication and optimal ON DBS, 
off PD medication sessions.  Due to technical difficulties, one participant did not have SSAI 
scores and another did not have VAS scores on contact manipulation days.  Both of these 
participants were diagnosed with remitted mood disorders.   
Acute effects of STN DBS on mood and motor behavior 
Since UPDRS scores consist of ranks, a paired Wilcoxon signed ranks test was used to 
test for differences in UPDRS scores between OFF DBS, off PD medication and optimal ON 
STN DBS, off PD medication conditions; paired t-tests were used for VAS valence, anxiety, 
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 Modulation of STN DBS-induced changes in mood and motor behavior by psychiatric diagnosis 
General linear model (GLM) univariate and non-parametric Kruskal-Wallis analyses of 
variance (ANOVA)  determined if age, disease duration, time between DBS surgery and Initial 
Interview, proportion of participants currently taking psychiatric medications, SSAI scores 
(during Initial Interview), BDI scores and race and gender distributions differed across 3 groups 
of participants, including 1) participants diagnosed with a current mood and/or anxiety disorder 
(n = 15; these participants may also have remitted mood and/or anxiety disorders); 2) participants 
diagnosed with a remitted mood or anxiety disorder (n = 11, no current diagnosis); and 3) 
participants deemed to have never met threshold criteria for a mood or anxiety disorder diagnosis 
(n = 12).  UPDRS , SSAI, VAS valence, VAS arousal, VAS anxiety and VAS apathy scores 
obtained during the OFF DBS, off PD medications condition were also compared across groups 
with Kruskal-Wallis or univariate ANOVA. 
Difference scores for all dependent variables were calculated by subtracting scores 
obtained during OFF DBS, off PD medication from those obtained during optimal ON DBS, off 
PD medication conditions.  To avoid Type I error due to multiple comparisons and because VAS 
measures can be highly correlated with each other although they represent different aspects of 
mood, two separate GLM multivariate ANOVA (MANOVA) were performed to determine 
whether diagnosis group, as described above, modulated STN DBS-induced VAS difference 
scores.  Since valence and arousal are the main constructs that represent emotional state in the 
circumplex model of emotion [33] and are scored on the same scale, valence and arousal 
difference scores were included as dependent variables in the first MANOVA.    The second 
MANOVA included VAS anxiety and apathy difference scores as dependent variables.  
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were followed up with post hoc least square difference comparisons. STN DBS-induced 
differences in SSAI and UPDRS scores were compared across the three diagnosis groups with a 
univariate ANOVA and a non-parametric Kruskal-Wallis ANOVA, respectively.   
Modulation of STN DBS-induced changes in mood and motor behavior by psychiatric symptom 
severity 
The influence of psychiatric symptom severity (measured by the BDI and SSAI during 
the Initial Interview) on STN DBS induced changes in VAS mood scores were tested in a 
manner similar to the MANOVAs described in the paragraph above except that BDI or SSAI 
was treated as a covariate and all participants were included in the analyses instead of partitioned 
into groups based on SCID diagnoses.  Pearson’s r or Spearman’s ρ tested for relationships 
between Initial Interview BDI or SSAI (from Initial Interview) scores and SSAI (from contact 
manipulation days) and UPDRS difference scores, respectively.  
Relationships between STN DBS-induced changes in mood variables and motor behavior 
To determine if STN DBS-induced changes in mood were related to changes in motor 
function, correlations between mood and UPDRS difference scores were performed with 
Spearman’s ρ across all participants as well as within diagnostic groups.    
The threshold for significance for all analyses was set at p ≤ 0.05, followed by Bonferroni 
multiple comparisons correction when appropriate.  
Results 
Participants 
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Stimulation Parameters and Clinical Contact Locations 
All participants had bilateral STN DBS with a monopolar configuration, with 185 Hz 
frequency, 1.3 – 3.6 V amplitude, and 60 or 90 µs pulse width.  STN DBS contact locations were 
mostly localized to the posterior STN and adjacent regions (see Figure 2).   
Acute Effects of STN DBS 
Relative to OFF DBS (off PD medications), optimal ON DBS (off PD medications) 
improved motor symptoms (UPDRS: Z37 = -4.64, p < 0.001), self-rated anxiety (VAS: t36 = 4.45, 
p < 0.001; SSAI: t36 = 2.56, p < 0.05), apathy (VAS: t36 = 3.37, p <  0.01) and affective valence 
(VAS: t36 = -4.72, p < 0.001), but did not affect affective arousal (VAS: t36 = 0.10, p = 0.93) (see 
Figure 3). Multiple comparisons correction was not applied here because we predicted that STN 
DBS would improve mood and motor function based on previous results from our laboratory 
[11]. 
Clinician Diagnoses and Symptom Severity 
Tables 2 and 3 detail the distribution of subjects according to SCID diagnosis at the 
Initial Interview and psychiatric medication use.   
Modulation of STN DBS-induced changes in mood and motor behavior by psychiatric diagnosis 
Participants with a current mood or anxiety disorder diagnosis (n = 15) did not differ 
from those with remitted diagnoses (n = 11) or from participants deemed to have never met 
threshold for diagnoses (n = 12) in age (p = 0.14), disease duration (p = 0.92; data missing for 1 
participant in the group of participants in the non-diagnosed group), the number of months 
between STN DBS surgery and the Initial Interview (p = 0.55), gender (p = 0.64), proportion of 
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scores (p = 0.32). Racial distribution did differ among diagnosis groups (p < 0.05) (Table 4).  
SSAI (p = 0.69), VAS valence (p = 0.39), VAS arousal (p = 0.45), VAS anxiety (p = 0.34), VAS 
apathy (p = 0.21) and UPDRS (p = 0.12; see Table 4) scores obtained during the OFF DBS, off 
PD medication condition did not differ across groups.  
Participants with current mood or anxiety disorder diagnoses experienced increased STN 
DBS-induced improvement in valence and anxiety (as measured by VAS) but not arousal or 
apathy compared to participants who were remitted or deemed to never have met threshold for 
diagnosis. (Figure 4A-B, Table 5).  STN DBS-induced changes in SSAI (F2,34 = 67.36, p = 0.47) 
and UPDRS (Χ236 = 1.03, p = 0.60) scores did not differ across the three diagnosis groups (data 
not shown). 
Modulation of STN DBS-induced changes in mood and motor behavior by psychiatric symptom 
severity  
BDI-II scores obtained during the Initial Interview (optimal ON, on medications) did not 
significantly modulate STN DBS-induced changes in any VAS measure (valence and arousal 
MANCOVA: F2,34 = 0.90, p = 0.42; anxiety and apathy MANCOVA:  F2,34 = 0.53, p = 0.59), 
SSAI (r37 = 0.22, p = 0.19) or UPDRS (ρ38 = 0.21, p = 0.21) scores (data not shown).   
SSAI scores obtained during the Initial Interview (optimal ON, on medications) did not 
significantly modulate STN DBS-induced changes in any VAS measure (valence and arousal 
MANCOVA: F2,34 = 1.51, p = 0.24; anxiety and apathy MANCOVA:  F2,34 = 0.16, p = 0.85), 
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Relationships Between Motor and Mood Responses to STN DBS 
 Across all participants (n = 37 excluding 1 participant each for VAS and SSAI analyses 
due to missing scores), DBS-induced change in UPDRS scores did not significantly correlate 
with DBS-induced change in anxiety (VAS:  ρ37 = 0.04, p = 0.80; SSAI: ρ37 = 0.22, p = 0.18), 
apathy (ρ37 = 0.11, p = 0.51), valence (ρ37 = -0.01, p = 0.97) or arousal (ρ37  = -0.06, p = 0.71) 
(data not shown).    STN DBS-induced changes in self-rated VAS and SSAI scores also were not 
significantly related to DBS-induced change in UPDRS scores within any diagnostic group: 1) 
participants who had current mood or anxiety diagnoses (n = 15) (ρ15 ≤ 0.51, p  ≥  0.05 for all 
correlations, data not shown); 2) participants diagnosed with remitted mood or anxiety disorders 
(n = 10) (ρ10  ≤ 0.58, p  ≥  0.08 for all correlations, data not shown); 3) participants deemed to 
never have had a threshold-level current or remitted mood or anxiety disorder (n = 12) (ρ12  ≤ 
0.18, p  ≥  0.57 for all correlations, data not shown).  None of the correlational p-values survived 
Bonferroni multiple comparisons corrections. 
Discussion 
The current study is the first analysis of the influence of mood or anxiety disorder 
diagnoses and self-reported psychiatric symptom severity on acute mood response to STN DBS 
with a rigorous OFF vs. ON DBS experimental design while off PD medications. As expected, 
STN DBS exerted acute positive effects on mood and motor behavior. Unexpectedly, PD 
participants diagnosed with current mood or anxiety disorders were more sensitive to the 
beneficial mood effects of STN DBS than those that did not meet threshold criteria for current 
diagnosis.  Although STN DBS acutely improved motor manifestations, change in motor 
function did not correlate with change in self-rated mood, suggesting that these effects occurred 
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current mood or anxiety disorders in PD alter the response of mood-related circuitry to STN 
DBS and provide further evidence that the STN is a functionally heterogeneous brain region 
embedded in both sensorimotor and limbic circuitry [5-6,8].  
Bilateral STN DBS acutely decreased self-reported anxiety and apathy while increasing 
affective valence, but did not affect emotional arousal.  These results support previous studies 
with similar experimental designs (ON vs. OFF stimulation, off PD medications) [11-13]. 
Replication of these findings both at a different clinical site from those in previous studies [12-
13] and within our own laboratory [11] provides strong evidence for their validity.  However, our 
results do contrast with those of other studies [17-19] in which STN DBS induced adverse 
effects on mood.  However, these psychiatric adverse effects appear to occur in some but not all 
PD patients in one study [19], and the other two are retrospective case reports [17-18].  
Importantly, none of these studies [17-19] employed planned experiments designed to test for 
acute changes in mood induced by STN DBS with an OFF control condition.  Furthermore, as 
described and as shown in Figure 2, the optimal STN DBS contact locations for participants in 
our study were in and around the caudal dorsolateral STN region, which is the surgical target for 
STN DBS.  Perhaps DBS at more ventral STN sites induces more profound and/or adverse 
effects on mood.   Indeed, DBS of dorsal and ventral/ventromedial regions of the STN is widely 
hypothesized to be disproportionately associated with alterations in motor behavior and mood, 
respectively [35-38]. 
Contrary to our hypothesis, PD participants diagnosed with current mood or anxiety 
disorders were more sensitive to STN DBS-induced improvements in valence and anxiety, as 
measured by VAS, than those that were deemed to be remitted or to not have ever met threshold 
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STN DBS-induced benefit in mood solely due to worse mood state at baseline since, relative to 
the remitted group and participants that were deemed to have never met criteria for diagnosis, 
they did not differ in BDI or SSAI scores during the Initial Interview or VAS or SSAI scores 
during the OFF DBS, off medication condition.  Given that the study was designed to carefully 
control for confounding effects such as placebo, lesion, and PD medications, it seems reasonable 
to infer that PD participants diagnosed with current mood or anxiety disorders likely have 
disturbed brain circuitry that is acutely more responsive to STN DBS compared to PD 
participants not currently diagnosed. In PD participants remitted for mood or anxiety disorders, 
this system may not be more responsive to STN DBS compared to participants never meeting 
criteria for a mood or anxiety disorder diagnosis because the disorder occurred prior to the onset 
of PD and/or disturbed circuitry may be recovered due to medication, other therapy, spontaneous 
remission, possibly ongoing STN DBS or any combination of these factors.  STN DBS may 
acutely improve mood and anxiety by affecting neurotransmission and/or other signaling features 
of the motor, associative and limbic circuitry that project to and/or receive input from the STN.   
The exact mechanism by which high-frequency DBS exerts its effects remains unknown but it 
likely reduces disturbances in basal ganglia thalamocortical network activity by increasing both 
excitatory and inhibitory signaling in the STN and adjacent fiber tracts [39].  In our study, DBS-
induced improvements in self-rated mood and anxiety did not correlate with improved motor 
function. Our findings suggest that optimized STN DBS can impact mood-related neural 
circuitry in addition to and/or separately from its effects on motor symptoms.  
Self-reported depressive and anxiety symptoms as measured by BDI and SSAI, 
respectively, did not modulate mood response to STN DBS.  BDI and SSAI scores also did not 
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without; nor did they differ between PD participants remitted for these disorders and those 
deemed to have never met criteria for diagnosis.  These results are surprising because study 
participants completed these questionnaires at a maximum of one week prior to contact 
manipulation days, suggesting that relatively recent self-reported symptom severity is not 
necessarily an accurate indicator of current or past threshold-level clinical symptoms of mood 
and anxiety disorders in PD.  Furthermore, our findings indicate that self-reported symptom 
severity does not predict mood or anxiety response to STN DBS while categorical clinical 
diagnosis does.  Interestingly, unlike VAS anxiety scores, psychiatric diagnosis did not modulate 
STN DBS-induced changes in SSAI scores.  The causes and implications of these findings 
deserve further study.  
There are some limitations to this study.  First, the majority of current SCID-diagnosed 
psychiatric disorders in this study were anxiety disorders whereas past SCID-diagnosed 
psychiatric disorders were primarily mood disorders.  The current study was not designed to test 
for differential modulation of acute mood response by mood vs. anxiety disorders.  The small 
sample size and overlap of these symptoms in the same participants limits our ability to 
disentangle the influence of these two types of disorders. Indeed, all 3 participants diagnosed 
with current mood disorders were also diagnosed with current anxiety disorders.   
Second, although participants were blinded to stimulation condition, fatigue and relief to 
be nearly done with the study could contribute to improved mood and/or motor behavior since 
the optimal ON condition was the last stimulation condition of the day.  However, similar results 
from our laboratory [11] and others [12-13] in which OFF and ON DBS conditions were 
randomized indicate that observed acute effects of STN DBS on mood and anxiety in our study 
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the study day shows that, with the exception of arousal, mood and motor function do not appear 
to improve over time (Figure 1, Appendix).  It is also possible that DBS effects did not 
completely dissipate during the OFF DBS, off medication condition, which may account for the 
lack of difference among diagnostic groups on the SSAI and VAS measures.  Indeed, reversible 
neuropsychiatric symptom rebounds are associated with gradualDBS (in regions other than STN) 
battery depletion over time for treatment-resistant depression [40] and obsessive compulsive 
disorder [41].  Since we investigated acute rather than long-term DBS effects , long-term 
wearing-off of DBS most likely does not account for diagnostic group differences in mood 
responsivity.  
Finally, we controlled for PD medication but not psychiatric medication use.  However, 
as detailed in Table 2, a substantial number of PD participants who were diagnosed with 
remitted or deemed to never have had a mood or anxiety disorder were taking psychiatric 
medications during the study and the proportion of participants with current diagnoses that were 
taking psychiatric medications did not differ between these groups.  Therefore, although future 
studies should include investigation of psychiatric medication effects on behavior, it is unlikely 
that psychiatric medication is responsible for the positive modulation of mood response to STN 
DBS by current mood or anxiety disorder diagnoses. 
Conclusions 
 PD participants diagnosed with current mood or anxiety disorders are more sensitive to 
STN DBS-induced improvements in mood, a possible indication that basal ganglia circuitry may 
be further altered in this group relative to those with remitted disorders or those deemed to have 
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STN plays a role in both motor and psychiatric manifestations in PD and may serve as an 
integration site for motor and limbic information as suggested by Haynes and Haber [5].  Future 
studies should investigate the effect of prolonged STN DBS on mood with longitudinal studies as 
well as the impact of baseline psychiatric symptomatology on the relationship between STN 
DBS location and alterations in mood in PD.   
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18 M, 20 F 
Age (years) 63.0 (8.0) 
Race 34 White, 1 Black, 3 Native American 
Duration of PD (years) 13.6 (5.0) 
Months from surgery to participation 15.5 (8.4) 
UPDRS Motor Score (OFF stimulation, off PD 
medication) 
33.9 (11.4) 
BDI-II Score 10.0 (5.5); range = 0-21 
SSAI Score 30.4 (7.3); range = 20-45 
Psychiatric Medication Type α, * None, n = 15; SSRI, n = 8; SNRI, n = 1; 
TeCA, n = 3; TCA n = 2; nTCA n = 3; 
BZD/BZD-like n = 11; Other n = 2 
Mean (S.D.) shown.  
α
, Participants may take more than 1 type of psychiatric medication. 
*, data not obtained from 2 participants. 
 BDI-II, Beck Depression Inventory II; SSAI, Spielberger State Anxiety Inventory; SSRI, 
selective serotonin reuptake inhibitor; SNRI, serotonin and norepinephrine inhibitor; TeCA, 
tetracyclic antidepressant; TCA, tricyclic antidepressant; nTCA, non-tricyclic antidepressant 
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Table 2.  Distribution of diagnosed disorders among PD participants in sample.   
 
SCID-I/NP Diagnoses α 
 
Number of participants 
 




Current mood disorder 3 3 
 
Remitted mood disorder 15 13 
 
No mood disorder ever 21 6 
 
Current anxiety disorder 15 9 
 
Remitted anxiety disorder 5 3 
 
No anxiety disorder ever 19 9 
α
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Mood Disorders   
             Major Depressive Disorder 10 2 
             Depressive Disorder NOS 3 1 
             Substance Induced  1 0 
   
Anxiety Disorders   
              Social Phobia 3 6 
              Specific Phobia 0 4 
              Anxiety Disorder NOS 0 4 
              Panic Disorder without Agoraphobia 1 1 
              Obsessive Compulsive Disorder 1 0 
α
, Participants may be diagnosed with more than one disorder.  SCID, Structural Clinical 
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Table 4.  Participant characteristics by SCID diagnosis group. 
 
Current Mood or 
Anxiety Disorder 
Diagnosis (n = 15) 
Remitted Mood  or 
Anxiety Disorder 
Diagnosis (n = 11) 
No Mood or Anxiety 
Disorder Diagnosis 
Ever (n = 12) 
 
Sex 6 M, 9 F 5 M, 6 F 7 M, 5 F 
 
Age (years) 60.9 (7.7) 61.6 (9.3) 66.8 (6.4) 
    
 
Race 
11 White, 1 Black, 3 
Native American 11 White 12 White 
 
Duration of PD (years) 13.8 (5.4) 13.1 (4.9) 13.9α (5.0) 
 
Months from surgery to 
participation 16.5 (7.1) 16.5 (10.3) 13.2 (8.2) 
 
UPDRS Motor Score 
(OFF DBS, off PD 
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Table 5.  Results for MANOVAs: Diagnostic group modulation of STN DBS-induced changes in VAS measures.  Current diagnosis n 
= 15; remitted diagnoses n = 10; no diagnosis ever n = 12.  Also, see Figure 4. 
Dependent Measure Main effect of Diagnostic Group 
Main effect of Diagnostic Group 
by VAS measure post hoc LSD results 
VAS Valence and Arousal 
Difference Scores F4,68 = 2.56, p = 0.046 





Arousal: F2,34 = 1.92, p = 0.162 
 
Valence: 
current vs. remitted, p = 0.009; 
current vs. never, p = 0.027; 
remitted vs. never,  p = 0.575 
 
Arousal: N/A (no main effect) 
 
    
VAS Anxiety and Apathy 
Difference Scores F4,68 = 3.27, p = 0.016 





Apathy: F2,34 = 0.94, p = 0.401 
 
Anxiety: 
current vs. remitted, p = 0.005; 
current vs. never, p = 0.014; 
remitted vs. never,  p = 0.308 
 


















Figure 1.  Experimental procedure detailing interviews, self-report questionnaires, motor 
assessment, and computer tasks (Visual Analogue Scales self-ratings) from which dependent 
variables were obtained.  Participants underwent contact manipulation conditions 1-7 days after 
the Initial Interview.  In the case of participants who underwent 2 days of stimulation conditions, 
OFF STN DBS dependent measure scores were obtained by averaging across both OFF 
conditions.   
 
Figure 2.  Three-dimensional distribution of clinically optimized STN DBS electrode contacts 
for the sample studied (N = 38).  They are presented (A) coronally and (B) sagittally, overlaid on 
the Mai atlas [25], 17.2 mm posterior to the anterior commissure.  For display purposes, a 0.75 
mm radius sphere was centered on each contact location.  Violet = STN; red spheres = right 
electrode contact locations; green spheres = left electrode contact locations. 
 
Figure 3.  Acute effects of STN DBS on mood and motor behavior.  Relative to OFF DBS (off 
PD medications), clinically optimal STN DBS (off PD medications) (A) improved motor 
symptoms, (B, D) decreased anxiety and apathy, and (C) increased valence (improved mood), 
but had no effect on emotional arousal.  Mean + SEM shown.  *, p < 0.05, **, p < 0.01, ***, p < 
0.001 relative to OFF.  VAS, visual analogue scale; SSAI, Spielberger State Anxiety Inventory; 
UPDRS, United Parkinson’s Disease Rating Scale. 
 
Figure 4.  STN DBS-induced improvements in mood are greater in participants with current 
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never to have met threshold criteria for diagnosis.  Optimal ON, off medication STN DBS-
induced improvements in self-rated (A) valence but not arousal and (B) anxiety but not apathy 
were significantly elevated in currently diagnosed participants relative to remitted and never 
diagnosed groups. Mean + SEM shown.  *, p < 0.05 relative to no diagnosis ever; ##, p < 0.01 



































































Figure 1. Improved motor and mood scores, with the possible exception of arousal, during 
optimal ON STN DBS, off medication do not appear to be due to the passage of time (relief to be 

























































































variable (A) UPDRS, (B) VAS anxiety, (C) VAS apathy, (D) VAS valence, (E) VAS arousal and 
(F) SSAI anxiety were averaged over stimulation conditions over 2 contact manipulation days.  
As part of a larger study, participants underwent up to 7 conditions of  DBS in various regions of 
the STN.  There were up to 4 conditions a day.  Optimal ON STN DBS was always the fourth 
and last condition.  Only the OFF and optimal ON STN DBS data is analyzed and presented in 
the manuscript.  Mean ± SEM shown.   N = 33-38 per data point. Variability in n is due to lost 















“Acute changes in mood induced by subthalamic deep brain stimulation in Parkinson disease are 
modulated by psychiatric diagnosis” (original Ms. Ref. No.: BRS-D-14-00109) by SA 
Eisenstein, WB Dewispelaere, MC Campbell, HM Lugar, JS Perlmutter, KJ Black, T Hershey. 
 
• Motor and mood responses to acute STN DBS were studied in 38 PD participants. 
• STN DBS improved motor and mood outcomes relative to OFF DBS. 
• Current psychiatric diagnosis was related to increased DBS-induced mood benefit. 
• Brain circuitry may be altered in PD participants with psychiatric diagnoses. 
